Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing…
Himax Subsidiary Liqxtal Technology Pro-Eye Vision Care Display Makes its Medical Taiwan 2025 Debut
TAINAN, Taiwan, May 29, 2025 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq:…
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements…
New Data at DDW 2025 Further Demonstrates the TissueCypher Test’s Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
Additionally, an expert physician panel convened by EndoscopyNow will host a product…
Pfizers Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Nave, High-Risk Non-Muscle Invasive Bladder Cancer
Pivotal Phase 3 CREST trial results show a 32% reduction in the…
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
April 23, 2025 17:23 ET | Source: Mineralys Therapeutics, Inc. – Significant…
Siemens Applauded by Frost & Sullivan for Supporting the Evolution of Smart Hospitals and Its Market-leading Position
Siemens strengthens its leadership position in the healthcare sector with its competency…
ELLKAY Names Ajay Kapare CEO
Longtime healthcare leader steps into CEO role to propel the company's next…
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy…
Patients experienced a 38% reduction in the risk of disease progression or…